Can-Fite BioPharma (CANF) has completed enrolment of the first 247 patients in its pivotal phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis, the company said Monday.
The study has now reached a pre-specified interim stage under a protocol agreed with both the US Food and Drug Administration and the European Medicines Agency, the company said.
Results from the study are expected during Q4 2026 or Q1 2027, the company said.
Shares of the company were up 2.3% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments